Cleared Traditional

K133397 - P-POD

K133397 is an FDA 510(k) clearance for P-POD, manufactured by P-Pod. The device is a Class 2 Neurology device with product code MVA cleared through the Traditional 510(k) pathway after a 163-day FDA review.

K133397 · P-Pod · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2014
Decision
163d
Days
Class 2
Risk

K133397 is an FDA 510(k) clearance for the P-POD. Classified as Orthosis, Cranial (product code MVA), Class II - Special Controls.

Submitted by P-Pod (Woodstock, US). The FDA issued a Cleared decision on April 18, 2014 after a review of 163 days - an extended review cycle.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.5970 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Neurology review framework, consistent with the majority of Class II 510(k) submissions.

View all P-Pod devices

FDA 510(k) Submission Details - K133397

510(k) Number K133397 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 06, 2013
Decision Date April 18, 2014
Days to Decision 163 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
15d slower than avg
Panel avg: 148d · This submission: 163d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

MVA Device Classification - Class 2, Special Controls

Product Code MVA Orthosis, Cranial
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.5970
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.